Bio Pharma Dive

APRIL 24, 2022

A study testing Alnylam's drug Onpattro in a deadly heart condition was once seen as a sure bet. Now the trial is the source of much debate, and its outcome could influence how future treatments for the disease are developed.

Trials 283

Trials Development Drugs 283

Bio Pharma Dive

AUGUST 3, 2023

The biotech is acquiring rights to an RNA interference medicine Alnylam invented for a rare blood disorder, continuing a corporate makeover that began in 2020.

RNA 130

RNA Medicine 130

Bio Pharma Dive

NOVEMBER 24, 2020

Like other Alnylam drugs, it comes at a six-figure list price. The drug, now known as Oxlumo, is the first approved treatment for patients with a potentially life-threatening condition that can cause kidney failure.

Drugs 291

Drugs 291

Pharmaceutical Technology

JULY 24, 2023

Roche has announced a collaboration with Alnylam for the development and marketing of zilebesiran to treat hypertension.

Development 130

Development Marketing 130

Pharmaceutical Technology

FEBRUARY 8, 2024

Cemdisiran is under clinical development by Alnylam Pharmaceuticals and currently in Phase III for Myasthenia Gravis.

Clinical Development 100

Clinical Development Development 100

Fierce Pharma

APRIL 22, 2024

As a closely watched readout from Alnylam Pharmaceuticals' Amvuttra in the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM) is expected in a few weeks, experts suggested the RNA si | As an all-important readout from Alnylam’s Amvuttra in the rare heart disease ATTR-CM is expected in a few weeks, experts suggested that the RNA (..)

RNA 94

RNA Trials 94

Bio Pharma Dive

JULY 28, 2022

Important data from the APOLLO study of the biotech's drug Onpattro are due before the end of August, Alnylam said Thursday.

Drug Trials 166

Drug Trials Drugs Trials 166

BioSpace

SEPTEMBER 11, 2023

After a three-month delay, GSK expects an FDA verdict for its myelofibrosis candidate, while Alnylam gears up for an advisory committee meeting discussing patisiran in cardiomyopathy of ATTR amyloidosis.

103

103

Fierce Pharma

FEBRUARY 15, 2024

That’s exactly what Alnylam just did for a closely watched study of its next-generation RNA interference therapy Amvuttra in a rare heart disease. Changing a clinical trial’s statistical analysis plan on the cusp of a readout? Changing a clinical trial’s statistical analysis plan on the cusp of a readout?

RNA 103

RNA Trials 103

Drug Patent Watch

MARCH 7, 2024

Annual Drug Patent Expirations for GIVLAARI Givlaari is a drug marketed by Alnylam Pharms Inc and is included in one NDA. There are twelve… The post New patent expiration for Alnylam Pharms drug GIVLAARI appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

Drugs 59

Drugs Marketing 59

Bio Pharma Dive

APRIL 4, 2022

The FDA has yet to sign off on a third-party packaging and labeling facility that Alnylam planned to help launch its drug, called vutrisiran, meaning an approval decision could come as late as mid-July.

RNA 150

RNA Packaging Packaging Drugs 150

Fierce Pharma

JANUARY 3, 2024

Morgan Healthcare Conference rolled on in San Francisco, BioNTech, Alnylam and many other companies updated investors on their strategies heading into 2024. As the J.P. | As the J.P.

Sales 116

Sales Vaccination Vaccine 116

BioSpace

OCTOBER 25, 2023

Following the regulator’s denial of patisiran’s label expansion, Alnylam has published late-stage data for the RNAi therapeutic in The New England Journal of Medicine demonstrating its efficacy in ATTR-cardiomyopathy.

Medicine 108

Medicine 108

Pharmaceutical Technology

AUGUST 11, 2022

Alnylam Pharmaceuticals and collaborators have identified rare mutations in the INHBE gene that is expressed in the liver, related to a lower waist-to-hip ratio for body mass index (BMI), which is often used as an indicator of abdominal fat and is correlated with the risk of type 2 diabetes (T2D) and coronary heart disease.

Gene 130

Gene Biobanking Gene Expression In-Vitro 130

pharmaphorum

SEPTEMBER 14, 2023

Alnylam's Onpattro clears FDA vote for ATTR-cardiomyopathy Phil.Taylor Thu, 14/09/2023 - 09:01 Bookmark this

105

105

Bio Pharma Dive

MARCH 5, 2024

The study results further validate Roche’s recent decision to acquire rights to the drug, which is being developed for people with a stubborn form of hypertension.

Drugs 290

Drugs Trials Development 290

Bio Pharma Dive

JANUARY 7, 2021

Late-stage results for vutrisiran look as though they'll help Alnylam deliver on the promise that RNAi technology can be a repeatable drug platform.

Drugs 201

Drugs 201

Drug Patent Watch

DECEMBER 31, 2023

Annual Drug Patent Expirations for GIVLAARI Givlaari is a drug marketed by Alnylam Pharms Inc and is included in one NDA. There are thirteen… The post New patent expiration for Alnylam Pharms drug GIVLAARI appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

Drugs 59

Drugs Marketing 59

Fierce Pharma

SEPTEMBER 18, 2023

With backing from an FDA advisory committee and results from a positive phase 3 trial, respectively, Alnylam and BridgeBio are each on track to enter the blockbuster transthyretin amyloidosis cardi | Alnylam and BridgeBio are each on track to enter the blockbuster transthyretin amyloidosis cardiomyopathy (ATTR-CM) market.

Doctors 95

Doctors Doctor Marketing Trials 95

Fierce Pharma

AUGUST 28, 2023

As Alnylam persists in its COVID-19 patent litigation, the RNAi specialist has been dealt a blow in one of its lawsuits against Moderna. | As Alnylam persists in its COVID-19 patent litigation, the RNAi specialist has been dealt a blow in one of its lawsuits against Moderna. But Alnylam says it'll appeal the recent ruling.

Vaccination 79

Vaccination Vaccine 79

BioSpace

JULY 23, 2023

With an upfront payment of $310 million in cash, Roche is partnering with Alnylam to develop the latter’s RNA interference candidate zilebesiran for hypertension patients with high cardiovascular risk.

RNA 93

RNA Development 93

pharmaphorum

SEPTEMBER 8, 2023

Lift for Roche as Alnylam drug lowers blood pressure Phil.Taylor Fri, 08/09/2023 - 07:31 Bookmark this

Drugs 105

Drugs 105

Drug Patent Watch

NOVEMBER 3, 2023

Annual Drug Patent Expirations for ONPATTRO Onpattro is a drug marketed by Alnylam Pharms Inc and is included in one NDA. There are sixteen… The post New patent expiration for Alnylam Pharms drug ONPATTRO appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

Drugs 59

Drugs Marketing 59

pharmaphorum

JULY 17, 2023

Alnylam showcases long-acting amyloid drug at AAIC Phil.Taylor Mon, 17/07/2023 - 08:47 Bookmark this

Drugs 98

Drugs 98

Fierce Pharma

SEPTEMBER 13, 2023

After Alnylam faced FDA doubts about its bid to expand RNA-silencing drug Onpattro into a rare heart disease called transthyretin amyloidosis cardiomyopathy (ATTR-CM), the company has picked up key | An FDA advisory committed voted in favor of Alnylam's bid to expand its RNA-silencing drug Onpattro into the rare heart disease called ATTR-CM.

RNA 82

RNA Drugs 82

BioSpace

JUNE 13, 2022

The FDA has approved Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults.

95

95

Fierce Pharma

MAY 30, 2023

Alnylam sticks with aggressive litigation strategy against Pfizer and Moderna, filing yet another patent lawsuit zbecker Tue, 05/30/2023 - 10:24

109

109

Fierce Pharma

OCTOBER 2, 2023

With FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam esagonowsky Mon, 10/02/2023 - 13:15

Drugs 89

Drugs 89

Fierce Pharma

SEPTEMBER 11, 2023

Ahead of an important advisory committee meeting, the FDA has raised serious questions about Alnylam’s bid to expand Onpattro into a much larger group of patients with transthyretin amyloidosis (AT | The FDA has raised questions about Alnylam's Onpattro as the company seeks to expand the drug into a much larger group of patients with transthyretin (..)

Drugs 100

Drugs 100

Drug Patent Watch

JUNE 7, 2023

Annual Drug Patent Expirations for GIVLAARI Givlaari is a drug marketed by Alnylam Pharms Inc and is included in one NDA. There are fourteen… The post New patent for Alnylam Pharms drug GIVLAARI appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

Drugs 52

Drugs Marketing 52

XTalks

MARCH 21, 2022

Credited as a pioneering RNA interference (RNAi) therapeutics company, Alnylam Pharmaceuticals is taking Pfizer and Moderna to court, claiming that the companies’ use of the lipid nanoparticle (LNP)-based RNA delivery technology in their mRNA COVID-19 vaccines infringes on a patented technology.

RNA 98

RNA Vaccination Vaccine Sales 98

Fierce Pharma

MAY 16, 2023

Moderna hits back at Alnylam's 'baseless' patent infringement claims zbecker Tue, 05/16/2023 - 15:59

87

87

Bio Pharma Dive

OCTOBER 2, 2023

The regulator is considering approval of what would be the first CRISPR medicine, as well as important clearances for Alnylam, Bristol Myers, Amgen and Pfizer.

Regulation 297

Regulation Medicine 297

BioSpace

APRIL 23, 2023

Ionis and AstraZeneca Seek to Challenge Alnylam with New ATTR Data 4/24/2023

101

101

Bio Pharma Dive

JULY 24, 2023

The Swiss pharma company is the latest large drugmaker to invest big in an experimental heart treatment, after years of prioritizing medicines for cancer and immune diseases.

Pharma Companies 246

Pharma Companies Research Medicine Drugs 246

Drug Patent Watch

JANUARY 9, 2023

Annual Drug Patent Expirations for GIVLAARI Givlaari is a drug marketed by Alnylam Pharms Inc and is included in one NDA. The post New patent for Alnylam Pharms drug GIVLAARI appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier. There are thirteen….

Drugs 52

Drugs Marketing 52

Pharma Times

OCTOBER 7, 2021

Leading RNA intereference (RNAi) therapeutics company, Alnylam, has been welcomed as the latest partner in the Medicines Manufacturing Innovation Centre, to transform the manufacturing process of oligonucleotide therapies.

Manufacturing 91

Manufacturing Medicine RNA 91